EyeGene Inc. (KOSDAQ:A185490) announced a private placement of 851,342 common shares at an issue price of KRW 14,800 for gross proceeds of KRW 12,599,861,600 on December 12, 2017. The shares issued have a face value of KRW 500. The transaction involved participation from Korea Investment Global Pharmaceutical Industry Promotion PEF, a fund managed by Korea Investment Partners Co.

Ltd. for 236,486 shares, Korea Investment Core Competence Leveraged Fund for 47,297 shares and Korea Investment Industry 4.0 Venture Fund for 47,297 shares. The shares will be issued at a premium. The shares will be issued through third party allotment method and are subject to a restricted period of one year.

Post the closing of the transaction, the shares issued by the company will increase from 10,115,000 to 10,966,342. The expected payment date of the transaction is December 14, 2017. The transaction was approved by the board of directors of the company.